Karuna Therapeutics 주식 주식분석 | 주식가격 | 뉴스 | KRTX | US48576A1007 | A2PM5N

날짜	Karuna Therapeutics 주식 가격
	329.83 undefined
	329.83 undefined

날짜	Karuna Therapeutics 매출	Karuna Therapeutics EBIT	Karuna Therapeutics 이익
2029e	3.39 조. undefined	0 undefined	1.32 조. undefined
2028e	2.35 조. undefined	1.27 조. undefined	964.14 백만 undefined
2027e	1.48 조. undefined	668.16 백만 undefined	512.97 백만 undefined
2026e	742.78 백만 undefined	21.15 백만 undefined	38.73 백만 undefined
2025e	261.14 백만 undefined	-351.35 백만 undefined	-314.6 백만 undefined
2024e	28.13 백만 undefined	-513.61 백만 undefined	-470.4 백만 undefined
2023	654,000 undefined	-494.78 백만 undefined	-433.68 백만 undefined
2022	10.64 백만 undefined	-289.68 백만 undefined	-276.34 백만 undefined
2021	36.96 백만 undefined	-143.86 백만 undefined	-143.81 백만 undefined
2020	0 undefined	-71.82 백만 undefined	-68.55 백만 undefined
2019	0 undefined	-45.41 백만 undefined	-43.96 백만 undefined
2018	0 undefined	-14.51 백만 undefined	-17.51 백만 undefined
2017	0 undefined	-4.81 백만 undefined	-6.03 백만 undefined

	매출	EBIT	이익
2017	0 USD	-4.81 백만 USD	-6.03 백만 USD
2018	0 USD	-14.51 백만 USD	-17.51 백만 USD
2019	0 USD	-45.41 백만 USD	-43.96 백만 USD
2020	0 USD	-71.82 백만 USD	-68.55 백만 USD
2021	36.96 백만 USD	-143.86 백만 USD	-143.81 백만 USD
2022	10.64 백만 USD	-289.68 백만 USD	-276.34 백만 USD
2023	654,000 USD	-494.78 백만 USD	-433.68 백만 USD
2024e	28.13 백만 USD	-513.61 백만 USD	-470.4 백만 USD
2025e	261.14 백만 USD	-351.35 백만 USD	-314.6 백만 USD
2026e	742.78 백만 USD	21.15 백만 USD	38.73 백만 USD
2027e	1.48 조. USD	668.16 백만 USD	512.97 백만 USD
2028e	2.35 조. USD	1.27 조. USD	964.14 백만 USD
2029e	3.39 조. USD	0 USD	1.32 조. USD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	0	0.04	0.01	0	0.03	0.26	0.74	1.48	2.35	3.39
-	-	-	-	-	-72.22	-	-	832.14	184.29	99.33	58.55	44.35
-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0
-0	-0.01	-0.05	-0.07	-0.14	-0.29	-0.49	-0.51	-0.35	0.02	0.67	1.27	0
-	-	-	-	-397.22	-2,890.00	-	-1,832.14	-134.48	2.83	45.17	54.07	-
-0.01	-0.02	-0.04	-0.07	-0.14	-0.28	-0.43	-0.47	-0.31	0.04	0.51	0.96	1.32
-	183.33	152.94	58.14	110.29	93.01	56.88	8.55	-33.19	-112.10	1,247.37	88.28	36.41
21.37	21.37	26.01	26.45	29.14	31.63	36.96	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

0	0.01	0.39	0.32	0.49	1.12	1.26
0	0	0	0	1.8	0.1	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.2	1.7	3.3	22.3	21.6	30.7	52.5
0	0.02	0.39	0.34	0.52	1.15	1.32
0	0.1	0.2	2.9	9.5	7.9	20.51
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	100	100	200	800	700	382
0	0.2	0.3	3.1	10.3	8.6	20.9
0	0.02	0.39	0.35	0.53	1.16	1.34

0	42	0	0	0	0	0
0	0	0.47	0.48	0.79	1.69	2.26
-14	-31.6	-75.5	-144.1	-287.9	-564.2	-997.89
0	0	0	0	-500	-3,300	211
0	0	0	0	0	0	0
-0.01	0.01	0.39	0.34	0.5	1.13	1.26
0.8	0.3	0.5	0.9	1.9	2.4	6.78
0.4	0.5	2.4	6	18.3	31.6	44.45
2.6	0.4	0	0	0	0	16.89
0	0	0	0	0	0	0
7.7	0	0	0	0	0	0
11.5	1.2	2.9	6.9	20.2	34	68.13
4	2.5	0	0	0	0	0
0	0	0	0	0	0	0
0	0.1	0.2	1.8	5.4	3.2	13.85
4	2.6	0.2	1.8	5.4	3.2	13.85
15.5	3.8	3.1	8.7	25.6	37.2	81.97
0	0.02	0.39	0.35	0.53	1.16	1.34

2017	2018	2019	2020	2021	2022	2023
-6	-17	-43	-68	-143	-276	-433
0	0	0	0	0	1,000	1,000
0	0	0	0	0	0	0
0	-1	0	-15	10	4	9
1	4	24	27	61	89	111
0	0	0	0	0	0	0
0	0	0	0	0	0	0
-4	-15	-30	-69	-100	-228	-385
0	0	0	0	-3	0	-2
0	-5	-174	-89	-22	-586	-160
0	-4	-174	-89	-19	-585	-157
0	0	0	0	0	0	0
4	11	3	0	0	0	0
0	15	404	4	277	856	488
4	27	405	3	277	855	483
-	-	-2.00	-	-	-	-4.00
0	0	0	0	0	0	0
0	7	200	-155	154	41	-62
-4.04	-15.51	-31.04	-70.28	-103.95	-228.93	-388.74
0	0	0	0	0	0	0

Karuna Therapeutics 브루토마진	Karuna Therapeutics EBIT-마진	Karuna Therapeutics 이익 마진
2029e	0 %	38.86 %
2028e	54.05 %	41.1 %
2027e	45.18 %	34.68 %
2026e	2.85 %	5.21 %
2025e	-134.54 %	-120.47 %
2024e	-1,825.71 %	-1,672.11 %
2023	-75,653.98 %	-66,311.93 %
2022	-2,722.56 %	-2,597.18 %
2021	-389.23 %	-389.1 %
2020	0 %	0 %
2019	0 %	0 %
2018	0 %	0 %
2017	0 %	0 %

	EBIT-마진	이익 마진
2017	0 %	0 %
2018	0 %	0 %
2019	0 %	0 %
2020	0 %	0 %
2021	-389.23 %	-389.1 %
2022	-2,722.56 %	-2,597.18 %
2023	-75,653.98 %	-66,311.93 %
2024e	-1,825.71 %	-1,672.11 %
2025e	-134.54 %	-120.47 %
2026e	2.85 %	5.21 %
2027e	45.18 %	34.68 %
2028e	54.05 %	41.1 %
2029e	0 %	38.86 %

날짜	Karuna Therapeutics 주당 매출	Karuna Therapeutics EBIT 당 주식	Karuna Therapeutics 주당 이익
2029e	88.73 undefined	0 undefined	34.48 undefined
2028e	61.49 undefined	0 undefined	25.27 undefined
2027e	38.77 undefined	0 undefined	13.45 undefined
2026e	19.47 undefined	0 undefined	1.02 undefined
2025e	6.85 undefined	0 undefined	-8.25 undefined
2024e	0.74 undefined	0 undefined	-12.33 undefined
2023	0.02 undefined	-13.39 undefined	-11.73 undefined
2022	0.34 undefined	-9.16 undefined	-8.74 undefined
2021	1.27 undefined	-4.94 undefined	-4.94 undefined
2020	0 undefined	-2.72 undefined	-2.59 undefined
2019	0 undefined	-1.75 undefined	-1.69 undefined
2018	0 undefined	-0.68 undefined	-0.82 undefined
2017	0 undefined	-0.23 undefined	-0.28 undefined

	주당 매출	EBIT 당 주식	주당 이익
2017	0 USD	-0.23 USD	-0.28 USD
2018	0 USD	-0.68 USD	-0.82 USD
2019	0 USD	-1.75 USD	-1.69 USD
2020	0 USD	-2.72 USD	-2.59 USD
2021	1.27 USD	-4.94 USD	-4.94 USD
2022	0.34 USD	-9.16 USD	-8.74 USD
2023	0.02 USD	-13.39 USD	-11.73 USD
2024e	0.74 USD	0 USD	-12.33 USD
2025e	6.85 USD	0 USD	-8.25 USD
2026e	19.47 USD	0 USD	1.02 USD
2027e	38.77 USD	0 USD	13.45 USD
2028e	61.49 USD	0 USD	25.27 USD
2029e	88.73 USD	0 USD	34.48 USD

	주식 수량
2017	21.37 백만 Aktien
2018	21.37 백만 Aktien
2019	26.01 백만 Aktien
2020	26.45 백만 Aktien
2021	29.14 백만 Aktien
2022	31.63 백만 Aktien
2023	36.96 백만 Aktien
2024e	36.96 백만 Aktien
2025e	36.96 백만 Aktien
2026e	36.96 백만 Aktien
2027e	36.96 백만 Aktien
2028e	36.96 백만 Aktien
2029e	36.96 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-2.7	-3.01 (-11.34 %)	2023 Q4
-2.8	-3.16 (-12.95 %)	2023 Q3
-2.83	-2.75 (2.87 %)	2023 Q2
-2.81	-2.8 (0.37 %)	2023 Q1
-2.29	-2.22 (3.11 %)	2022 Q4
-2.18	-2.38 (-9.32 %)	2022 Q3
-2.14	-2.17 (-1.58 %)	2022 Q2
-2.15	-1.95 (9.45 %)	2022 Q1
-1.77	-0.94 (46.86 %)	2021 Q4
-1.47	-1.72 (-17.03 %)	2021 Q3
-1.36	-1.17 (14.22 %)	2021 Q2
-1.15	-1.07 (7.21 %)	2021 Q1
-0.91	-0.89 (2.53 %)	2020 Q4
-0.84	-0.71 (15.27 %)	2020 Q3
-0.46	-0.65 (-40.27 %)	2020 Q2
-0.41	-0.33 (19.73 %)	2020 Q1
-0.48	-0.32 (33.76 %)	2019 Q4
-0.46	-0.39 (15.97 %)	2019 Q3
-0.89	-0.65 (26.59 %)	2019 Q2

%-지분	이름	주식	변경
8.43569 %	The Vanguard Group, Inc.	3,218,215	21,201
7.51056 %	Fidelity Management & Research Company LLC	2,865,278	-2,691,695
7.10257 %	T. Rowe Price Investment Management, Inc.	2,709,629	-32,828
5.03766 %	T. Rowe Price Associates, Inc.	1,921,869	-777,197
4.44435 %	BlackRock Institutional Trust Company, N.A.	1,695,518	50,701
4.01458 %	PureTech Health, L.L.C.	1,531,564	-125,000
3.62031 %	Sofinnova Investments, Inc	1,381,149	0
2.97260 %	Wellington Management Company, LLP	1,134,046	-151,462
2.79476 %	Pentwater Capital Management LP	1,066,200	1,037,700
2.58640 %	General Atlantic LLC	986,710	0
2.55477 %	State Street Global Advisors (US)	974,643	45,673
2.08914 %	Pivotal Bioventure Partners Investment Advisor LLC	797,008	0
1.49337 %	Geode Capital Management, L.L.C.	569,722	24,649
1.35000 %	Rock Springs Capital Management LP	515,024	9,591
1.17658 %	Capital International Investors	448,866	-3,778,236
1.10663 %	UBS Financial Services, Inc.	422,178	419,217
0.98861 %	AllianceBernstein L.P.	377,155	13,787
0.93702 %	Woodline Partners LP	357,473	334,751
0.87325 %	Brown Advisory	333,144	11,059
0.85994 %	Norges Bank Investment Management (NBIM)	328,067	16,582
0.82803 %	Balyasny Asset Management LP	315,892	208,093
0.77939 %	Invesco Advisers, Inc.	297,336	-15,709
0.75239 %	First Light Asset Management, LLC	287,037	-16,100
0.65531 %	Boxer Capital, L.L.C.	250,000	0
0.62295 %	Fiera Capital Corporation	237,656	199
0.59158 %	Nan Fung Life Sciences	225,688	0
0.58993 %	Charles Schwab Investment Management, Inc.	225,060	6,721
0.58453 %	Alpine Associates Management Inc.	223,000	223,000
0.53997 %	Avidity Partners Management LP	206,000	-80,700
0.52992 %	Magnetar Capital Partners LP	202,165	198,264
0.52701 %	Kryger Capital Limited	201,053	201,053
0.49901 %	Goldman Sachs Asset Management, L.P.	190,371	169,488
0.49803 %	Eventide Asset Management, LLC	190,000	-149,840
0.49630 %	TD Asset Management Inc.	189,340	-38,378
0.46880 %	Eagle Asset Management, Inc.	178,849	-26,930
0.45660 %	SG Americas Securities, L.L.C.	174,193	167,448
0.42724 %	Millennium Management LLC	162,991	64,988
0.41419 %	Citadel Advisors LLC	158,012	-31,585
0.38599 %	AQR Capital Management, LLC	147,256	143,172
0.38392 %	Ensign Peak Advisors, Inc.	146,467	5,129
0.37153 %	Citi Investment Research (US)	141,738	104,913
0.35946 %	Northern Trust Investments, Inc.	137,134	6,670
0.34153 %	PFM Health Sciences, LP	130,293	-7,916
0.33451 %	Nuveen LLC	127,614	-22,405
0.33082 %	Twin Capital Management, LLC	126,206	126,206
0.33029 %	BlackRock Financial Management, Inc.	126,004	-168
0.32765 %	Avoro Capital Advisors LLC	125,000	125,000
0.32146 %	Franklin Advisers, Inc.	122,636	-77,897
0.31679 %	BlackRock Asset Management Ireland Limited	120,857	-2,911
0.31405 %	Bank of Nova Scotia	119,810	119,810
0.31164 %	Morgan Stanley & Co. LLC	118,890	93,499
0.29106 %	Mellon Investments Corporation	111,039	-8,865
0.29068 %	Paul (Steven M)	110,895	-804
0.27727 %	ClearBridge Investments, LLC	105,780	11,390
0.27374 %	UBS Asset Management (Switzerland)	104,432	-18,731
0.26759 %	Allspring Global Investments, LLC	102,086	1,057
0.26518 %	Westchester Capital Management, LLC	101,166	101,166
0.25275 %	Driehaus Capital Management, LLC	96,424	5,745
0.24401 %	New York State Common Retirement Fund	93,089	-4,694
0.23591 %	Logos Global Management LLC	90,000	-25,000
0.23591 %	Carlson Capital, L.P.	90,000	90,000
0.22901 %	First Turn Management, LLC	87,369	87,369
0.22890 %	Water Island Capital, LLC	87,325	87,325
0.22068 %	Gabelli Funds, LLC	84,190	84,190
0.20408 %	Ignelzi (Troy A)	77,855	56,018
0.20408 %	Catalyst Private Wealth, L.L.C.	77,855	56,018
0.19558 %	Segantii Capital Management Limited	74,613	74,613
0.18194 %	Glazer Capital, LLC	69,410	69,410
0.18181 %	BNY Mellon Asset Management	69,359	-161
0.18152 %	The Clarius Group, LLC	69,248	-29,973
0.17956 %	Corient Private Wealth LLC	68,504	19,912
0.16941 %	Point72 Asset Management, L.P.	64,630	-283,170
0.16847 %	SEB Investment Management AB	64,273	55,374
0.16540 %	Schweizerische Nationalbank	63,100	-6,900
0.16514 %	P. Schoenfeld Asset Management LP	63,000	63,000
0.16182 %	Barclays Bank PLC	61,734	33,152
0.15697 %	Fidelity International	59,885	0
0.15625 %	AQR Arbitrage, LLC	59,608	59,608
0.15354 %	Tekla Capital Management LLC	58,577	5,125
0.15335 %	Neuberger Berman, LLC	58,503	57,215
0.14994 %	Candriam Belgium S.A.	57,201	-4,000
0.14994 %	Candriam Luxembourg S.A.	57,201	0
0.14417 %	Picton Mahoney Asset Management	55,000	55,000
0.13966 %	BioImpact Capital LLC	53,279	69
0.13602 %	Dimensional Fund Advisors, L.P.	51,891	10,334
0.13289 %	California Public Employees' Retirement System	50,696	0
0.13179 %	HSBC Global Asset Management (UK) Limited	50,277	50,277
0.13157 %	Melqart Asset Management (UK) Limited	50,194	50,194
0.13151 %	Rice Hall James & Associates, LLC	50,171	10,790
0.13028 %	DWS Investment GmbH	49,700	0
0.12620 %	Dafna Capital Management, LLC	48,145	-4,728
0.12558 %	Summit Partners Public Asset Management, LLC	47,910	-49,467
0.12366 %	Rhumbline Advisers Ltd. Partnership	47,175	-312
0.12320 %	Decheng Capital LLC	47,000	47,000
0.11812 %	American Century Investment Management, Inc.	45,064	823
0.11453 %	Rafferty Asset Management LLC	43,693	-4,667
0.11194 %	BofA Global Research (US)	42,705	22
0.11153 %	Florida State Board of Administration	42,548	1,485
0.11085 %	Connor, Clark & Lunn Investment Management Ltd.	42,289	-10,401
0.10940 %	Ostrum Asset Management	41,737	41,737

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
PureTech Health	공급업체고객	0,26	0,13	0,48	0,19	0,34	0,29
Eli Lilly	공급업체고객	0,04	-0,07	0,50	0,38	0,05	0,69
Zai Lab	공급업체고객	-0,07	0,54	0,27	0,25	0,12	-
Neuland Laboratories	공급업체고객	-0,29	0,41	0,32	0,27	0,21	0,54

What values and corporate philosophy does Karuna Therapeutics represent?

Karuna Therapeutics Inc is a biopharmaceutical company committed to developing innovative therapies for neuropsychiatric disorders. The company's values and corporate philosophy revolve around scientific excellence, patient-centricity, and a passion for improving the lives of individuals suffering from mental health conditions. Karuna Therapeutics Inc's dedicated team of experts combines cutting-edge science with rigorous research to address the unmet needs in the field of neuropsychiatry. By placing a strong emphasis on innovation, collaboration, and compassion, Karuna Therapeutics Inc aims to revolutionize the treatment options available to patients and make a positive impact in the mental health community.

In which countries and regions is Karuna Therapeutics primarily present?

Karuna Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Karuna Therapeutics achieved?

Karuna Therapeutics Inc has achieved several significant milestones. The company has successfully developed and advanced its lead product candidate, KarXT, into late-stage clinical trials. KarXT showed promising results in addressing the symptoms of schizophrenia in phase 2 clinical trials. Additionally, Karuna Therapeutics Inc successfully completed its initial public offering (IPO) in 2019, raising significant capital to support its research and development efforts. The company continues to collaborate with renowned academic institutions to expand its pipeline and explore novel treatments for central nervous system disorders. Overall, Karuna Therapeutics Inc has made notable progress in advancing innovative therapies to improve the lives of patients.

What is the history and background of the company Karuna Therapeutics?

Karuna Therapeutics Inc is a biopharmaceutical company founded in 2009. Based in Boston, Massachusetts, Karuna Therapeutics specializes in developing therapies for neuropsychiatric disorders. The company is dedicated to advancing innovative treatment options for patients suffering from conditions such as schizophrenia and Alzheimer's disease. Leveraging their extensive expertise in neuroscience and drug development, Karuna Therapeutics focuses on targeting muscarinic receptors in the brain to address unmet medical needs. With a strong commitment to improving patients' lives, Karuna Therapeutics is actively engaged in research and clinical trials, with the aim of bringing novel therapies to market that have the potential to revolutionize the treatment of these devastating disorders.

Who are the main competitors of Karuna Therapeutics in the market?

The main competitors of Karuna Therapeutics Inc in the market include other pharmaceutical companies that are also focused on developing innovative therapies for neuropsychiatric disorders. Some notable competitors in this space include Alkermes plc, Sage Therapeutics Inc, and Intra-Cellular Therapies Inc. These companies, like Karuna Therapeutics Inc, are dedicated to finding novel treatment options for conditions such as schizophrenia and Alzheimer's disease.

In which industries is Karuna Therapeutics primarily active?

Karuna Therapeutics Inc is primarily active in the biopharmaceutical industry.

What is the business model of Karuna Therapeutics?

The business model of Karuna Therapeutics Inc involves the development and commercialization of innovative therapies for the treatment of neuropsychiatric disorders. Karuna Therapeutics focuses on targeting muscarinic receptors in the brain to address conditions such as schizophrenia and Alzheimer's disease. By leveraging its proprietary KarXT platform, the company aims to deliver meaningful therapeutic benefits to patients and healthcare providers. Karuna Therapeutics combines its scientific expertise with strategic partnerships to accelerate the development and potential approval of its novel drug candidates. Through continuous research and clinical advancements, Karuna Therapeutics is dedicated to improving the lives of individuals affected by neuropsychiatric disorders.

Karuna Therapeutics 2024의 P/E 비율은 얼마입니까?

Karuna Therapeutics의 P/E 비율은 -25.91입니다.

Karuna Therapeutics 2024의 KUV는 얼마입니까?

Karuna Therapeutics의 P/S 비율은 433.32입니다.

Karuna Therapeutics의 AlleAktien 품질 점수는 얼마인가요?

Karuna Therapeutics에 대한 AlleAktien 품질 점수는 3/10입니다.

Karuna Therapeutics 2024의 매출은 얼마인가요?

예상되는 Karuna Therapeutics 매출은 28.13 백만 USD입니다.

Karuna Therapeutics 2024의 이익은 얼마인가요?

예상되는 Karuna Therapeutics 이익은 -470.4 백만 USD입니다.

Karuna Therapeutics은 무엇을 하나요?

Karuna Therapeutics Inc is a biopharmaceutical company that focuses on the discovery and development of novel drugs for the treatment of severe psychiatric and neurological disorders. Karuna's main focus is on the development of therapies for schizophrenia and Alzheimer's. The business model of Karuna Therapeutics is based on the discovery and development of innovative drugs that aim to counteract the underlying biological causes of psychiatric and neurological diseases. Karuna focuses on the development of drugs that have novel mechanisms of action and thus have the potential to revolutionize the treatment of severe diseases. The company has a wide range of drugs in its pipeline, covering various areas of psychiatry and neurology. One promising product from Karuna is KarXT, a biopharmaceutical drug combination consisting of xanomeline and trospium. KarXT is currently being developed as a potential treatment for schizophrenia and Alzheimer's. The company also has a strong presence in the field of clinical research and development. It works closely with leading researchers and clinics to develop and refine its products. In addition, Karuna has also established a number of business relationships with strategic partners and investors to finance and accelerate the development of its products. Karuna Therapeutics is a company that is highly focused on innovation and research. It sees itself as a pioneer in the development of drugs for severe neurological and psychiatric diseases and aims to develop groundbreaking therapies that have the potential to improve the lives of millions of people. The company also has a broad portfolio of patents based on various technologies and drug classes. This unique technology platform allows Karuna to further develop its drug pipeline and create innovative therapies for patients. Overall, Karuna Therapeutics pursues a multidisciplinary research and development program aimed at the discovery and development of novel drugs for the treatment of severe psychiatric and neurological disorders. Karuna's business model is designed to provide groundbreaking therapies that aim to counteract the underlying biological causes of diseases rather than just treating symptoms. The company also has a strong financial base to support its research and development initiatives. Karuna has strengthened its finances through strategic partnerships and investments in the company to realize its vision of providing novel therapies for serious diseases.

Karuna Therapeutics 배당금은 얼마입니까?

Karuna Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Karuna Therapeutics이 얼마나 자주 배당을 지급하나요?

Karuna Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Karuna Therapeutics ISIN이 무엇입니까?

Karuna Therapeutics의 ISIN은 US48576A1007입니다.

Karuna Therapeutics WKN은 무엇인가요?

Karuna Therapeutics의 WKN은 A2PM5N입니다.

Karuna Therapeutics 티커는 무엇인가요?

Karuna Therapeutics의 티커는 KRTX입니다.

Karuna Therapeutics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Karuna Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Karuna Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Karuna Therapeutics의 배당 수익률은 얼마입니까?

Karuna Therapeutics의 현재 배당 수익률은 입니다.

Karuna Therapeutics의 배당금은 언제 지급되나요?

Karuna Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Karuna Therapeutics의 배당금은 얼마나 안전한가요?

Karuna Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Karuna Therapeutics의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Karuna Therapeutics이(가) 속해 있는 섹터는 어디인가요?

Karuna Therapeutics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Karuna Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Karuna Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Karuna Therapeutics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Karuna Therapeutics의 2023년도 배당금은 얼마였습니까?

2023년에 Karuna Therapeutics는 0 USD를 배당금으로 지급했습니다.

Karuna Therapeutics는 어떤 화폐로 배당금을 지급하나요?

Karuna Therapeutics의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출	—
스코프 2 - 구매한 에너지로부터의 간접적인 배출	—
Scope 3 - 가치 창출 체인 내의 간접 배출	—
총 CO₂ 배출량	—
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	✅
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	❌
환경 친화적인 포장	❌
위험물질	❌
연료 소비량과 효율성	❌
물 사용량 및 효율성	❌

여성 직원 비율	—
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	❌
개인정보 보호 정책	—
작업 및 건강 보호	❌
카톨릭	✅

환경 보고	❌
이해관계자 참여	❌
콜백 정책	❌
카르텔법	❌

Karuna Therapeutics 티커	Karuna Therapeutics FIGI
KRTX:US	BBG00NN875G0
KRTX:UA	BBG00PBK8KC1
KRTX:UC	BBG00PBK8KD0
KRTX:UN	BBG00PBK8KG7
KRTX:UP	BBG00PBK8KH6
KRTX:UQ	BBG00PBK8KJ4
KRTX:UB	BBG00PBK8KK2
KRTX:UM	BBG00PBK8KM0
KRTX:UX	BBG00PBK8KN9
KRTX:UD	BBG00PBK8KT3
KRTX:UF	BBG00PBK8KX8
KRTX:VY	BBG00PBK8KY7
KRTX:VJ	BBG00PBK8KZ6
KRTX:VK	BBG00PBK8L02
KRTX:VF	BBG00PBK8L11
KRTX:VG	BBG00X1PHBQ9
KRTX:VP	BBG00X1SXR35
KRTX*:MM	BBG00X9DMSX7
KRTX*:MF	BBG00X9DMSY6
KRTX*:MU	BBG00X9DMSZ5
KRTXGBP:XS	BBG00ZFCD5Q5
KRTXGBP:XH	BBG00ZFCD5T2
KRTXGBP:XF	BBG00ZFCD5W8
KRTXGBP:XE	BBG00ZFCD5Y6
KRTXGBP:XL	BBG00ZFCD601
KRTXGBP:XG	BBG00ZFCD610
KRTXGBP:XO	BBG00ZFCD629
KRTXGBP:XA	BBG00ZFCD665
KRTXGBP:XT	BBG00ZFCD683
KRTXGBP:XW	BBG00ZFCD692
KRTXGBP:XU	BBG00ZFCD6B9
KRTXGBP:XV	BBG00ZFCD6D7
KRTXGBP:XM	BBG00ZFCD6F5
KRTXGBP:EU	BBG00ZFCD6N6
KRTXUSD:XH	BBG011N78211
KRTXUSD:XF	BBG011N78239
KRTXUSD:XE	BBG011N78257
KRTXUSD:XL	BBG011N78275
KRTXUSD:XG	BBG011N78284
KRTXUSD:XO	BBG011N78293
KRTXUSD:XA	BBG011N782F6
KRTXUSD:XT	BBG011N782H4
KRTXUSD:XW	BBG011N782J2
KRTXUSD:XU	BBG011N782K0
KRTXUSD:XV	BBG011N782M8
KRTXUSD:XM	BBG011N782N7
KRTXUSD:EU	BBG011N782X6

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커KRTX

ISINUS48576A1007

WKNA2PM5N

Karuna Therapeutics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Karuna Therapeutics 주가 이력

Karuna Therapeutics 주식 매출, EBIT, 이익 US48576A1007 · A2PM5N

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Karuna Therapeutics 매출, 이익 및 EBIT 역사

Karuna Therapeutics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Karuna Therapeutics 주식 마진 US48576A1007 · A2PM5N

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Karuna Therapeutics 마진 역사

Karuna Therapeutics 주식 매출, EBIT, 주당 순이익 US48576A1007 · A2PM5N

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Karuna Therapeutics 매출, 이익 및 EBIT 주당 역사

Karuna Therapeutics 주식 및 주식 분석

Karuna Therapeutics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Karuna Therapeutics 역사적인 P/E, EBIT 및 P/S에 따른 평가

Karuna Therapeutics 주식 수량 US48576A1007 · A2PM5N

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Karuna Therapeutics 수익 예상

Karuna Therapeutics 수익 놀라움

Eulerpool ESG Scorecard© Karuna Therapeutics 주식을 위해

Eulerpool World ESG Rating (EESG©)

31/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

Karuna Therapeutics 주식 주주 구조

Karuna Therapeutics 임원진 및 경영진

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
KRTX

ISIN
US48576A1007

WKN
A2PM5N